Advanced Nanosystems for Ophthalmic Administration
A special issue of Nanomaterials (ISSN 2079-4991).
Deadline for manuscript submissions: closed (30 September 2019) | Viewed by 14549
Special Issue Editor
Interests: lipid nanoparticles; microemulsions; ophthalmic therapeutics; anticancer therapy; retinal diseases; combinational therapies; in vitro preclinical models; veterinary medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ophthalmic therapies have recently been improved by the introduction of novel drug delivery approaches using implants or devices, advanced biomaterials, nanomedicines, stimuli-responsive systems, cell therapy, etc. These technologies are applied for the treatment of several anterior/posterior-segment diseases such as dry eye, allergy, inflammations, infections, glaucoma, cataract and retinal disorders (age-related macular degeneration, diabetic retinopathy, and others). Most of the inserts/implants are invasively applied and require surgical procedures, and advanced drug delivery systems (DDSs) based on nanotechnologies appear to provide more effective non-invasive therapies even though they require increasing efforts to obtain high clinical impacts. The employment of in vitro models to estimate the ocular drug release residence time and clearance plays an important role in this research progress. This Special Issue of Nanomaterials will survey the challenges and the current state-of-the-art in the use of nanomaterials to create advanced DDSs for the treatment of ocular diseases.
Dr. Simona Sapino
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ocular diseases
- Nanotechnologies
- Intraocular drug delivery
- Ocular barriers
- Ophthalmic implants
- Biomaterials
- Stimuli-responsive systems
- In vitro ocular models
- Cell cultures
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.